Epacadostat and Pembrolizumab in Patients With GIST
Status:
Completed
Trial end date:
2020-08-19
Target enrollment:
Participant gender:
Summary
Primary objective is to assess the efficacy of combined IDO and PD-1 inhibition in a single
arm phase II trial of epacadostat and pembrolizumab in patients with advanced
imatinib-refractory GIST, using a primary endpoint of overall response rate.
Secondary objectives are to evaluate the progression free survival (PFS), the overall
survival (OS), the response rate and to evaluate the safety and tolerability of combined
epacadostat and pembrolizumab treatment.
The investigator hypothesizes that treatment with epacadostat and pembrolizumab will increase
the response rate compared to what has been historically achieved with salvage tyrosine
kinase inhibitors.